research Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
Baricitinib is a promising treatment for alopecia areata.
Search
for
Sort by
Research
660-690 / 1000+ results 
research Search for New antineoplastic agents based on structural modifications of steroidal 5α-reductase, 17β-hydroxysteroid dehydrogenase, and 17α-hydroxylase/17,20-lyase inhibitors
Modifying steroidal inhibitors shows promise for developing new cancer treatments.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
research Multiple iridociliary cysts in patients with mucopolysaccharidoses
Intralesional cidofovir may be a viable alternative treatment for SCC.
research Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
research Bioactive peptides derived from food proteins preventing lifestyle‐related diseases
Food-derived peptides may help prevent diseases like high blood pressure and high cholesterol, and can support the immune system.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Torilin fromTorilis japonica,as a New Inhibitor of Testosterone 5α-Reductase
Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Glucocorticoid-Induced Side Effects Cause Oral Lesions in Systemic Lupus Erythematosus: A Case Report
Glucocorticoid treatment in lupus can cause oral lesions, which need early diagnosis and comprehensive care.
research JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.
research 0955 Selective BET inhibition as potential hidradenitis suppurativa treatment
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research The JAK/STAT signaling pathway: from bench to clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Optimized Nanostructured Lipid Carriers for Dutasteride Delivery: Improving Therapeutic Efficiency and Minimizing Adverse Effects
The new delivery method for dutasteride is more effective and has fewer side effects.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
research APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
JAK inhibitors may help improve symptoms in adults with APECED.
research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
research Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
research Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research SnapshotDx Quiz: September 2018
Tofacitinib may help regrow hair in alopecia areata patients.
research Alopecia – New building blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.